1. Background {#sec1}
=============

Atherosclerosis (AS) is a major public health problem worldwide that leads to various life-threatening complications, such as coronary artery disease, stroke, and peripheral artery disease \[[@B1], [@B2]\]. Traditional risk factors include hyperlipidemia, hypertension, diabetes mellitus, smoking, and a positive family history, but these do not fully explain the extent and severity of the conditions \[[@B3]\]. In recent years, numerous studies have implicated that pathogen burden might play an important role in the pathogenesis of atherosclerosis, for example,*Helicobacter pylori*,*Chlamydia pneumoniae*, and herpes simplex virus (HSV) \[[@B4]--[@B6]\].

HSV infection was widespread in the developed countries, with a prevalence of between 35% and 40% \[[@B7]\]. The data showed that the prevalence of HSV-1 and HSV-2 is 37% and 28%, respectively \[[@B7]\]. HSV was first proposed to be a risk factor for AS several decades ago when a chicken herpesvirus led to occlusive AS of large muscular arteries in an animal model \[[@B8]\]. Subsequent molecular biology and epidemiology studies have strengthened the hypothesis that HSV is an important risk factor in the development of AS in humans. The atherogenic mechanisms of HSV may involve increasing adherence of leukocytes to endothelium, inducing lipid accumulation in vascular smooth muscle cells (VSMCs), and contributing to deposition of thrombin in atherosclerotic plaques \[[@B9]--[@B11]\].

Recently an increasing number of epidemiologic studies have investigated the association between HSV infection and AS risk by testing HSV antibodies \[[@B12]\]. Siscovick et al. revealed that HSV-1 infection was associated with a 2-fold increase in the risk of incident MI and death from coronary heart disease \[[@B13]\]. Kis et al. detected increased levels of HSV-1 antibodies in patients with acute ischemic stroke, suggesting an association of HSV-1 infection with the disease \[[@B14]\]. The data of Guan et al. showed a higher prevalence of antibodies against HSV-2 in the subjects with acute myocardial infarction \[[@B15]\]. However, there were still some studies demonstrating no relationship between HSV infection and atherosclerosis \[[@B16], [@B17]\]. Given the controversial results of these studies, we deemed it necessary to conduct a quantitative and systematic assessment with rigorous methodology to further evaluate the potential role of HSV infection in the development of AS. We performed a meta-analysis to explore the relationship between HSV-1 and HSV-2 and AS risk.

2. Methods {#sec2}
==========

2.1. Publication Search {#sec2.1}
-----------------------

We searched the databases of PubMed, Web of Science, and CNKI (China National Knowledge Infrastructure) for articles on any relationship between HSV-1 and HSV-2 infection and the risk of developing AS. The last search date was March 15, 2015. The following key terms were used: "Herpes Simplex Virus OR HSV" and "atherosclerosis OR myocardial ischemia OR ischemic heart disease OR coronary artery disease OR angina OR myocardial infarction OR stroke OR cerebral ischemia OR carotid artery disease OR peripheral artery disease." The references cited in the research papers were further searched manually for potentially available publications.

2.2. Inclusion Criteria {#sec2.2}
-----------------------

\(1\) The study is a case-control design. (2) The study evaluates the association between HSV-1 and HSV-2 infection and AS risk. (3) The study confirms the diagnosis of the atherosclerotic diseases. (4) The study clearly supplies the values (or percentage) of positivity for HSV-1 and HSV-2 infection in cases and controls, respectively. (5) The study is published in English or Chinese.

2.3. Data Extraction {#sec2.3}
--------------------

Data from these studies were extracted by two of the authors (Yu peng Wu and Dan dan Sun) independently using a standardized form, who reached a consensus on all items. The following data were collected from each study: first author, year of publication, country, region, disease type, mean age, male proportion, detection method of HSV-1 and HSV-2 infection, sample size, and the positivity or negativity for HSV-1 and HSV-2 infection in cases and controls, respectively.

2.4. Statistical Analysis {#sec2.4}
-------------------------

The pooled odds ratios (OR) with 95% confidence intervals (CI) were used to assess the association of HSV-1 and HSV-2 infection with AS risk. Statistical heterogeneity between studies was assessed with the *χ* ^2^-based *Q* test and *I* ^2^ \[[@B18]\]. When heterogeneity was not an issue (*P* \> 0.10), a fixed-effect model with the Mantel-Haenszel method was used \[[@B19]\]. Otherwise, a random-effect model using the DerSimonian-Laird method was used \[[@B20]\]. Meanwhile, subgroup analysis was conducted for different geographic regions, male proportion, mean age, and disease types (divided into myocardial ischemia and other types of AS). To explore sources of heterogeneity across studies, we conducted logistic metaregression using the following study characteristics: region, test method, and positivity for HSV-1 and HSV-2 infection in controls. In addition, publication bias was evaluated qualitatively by performing funnel plots and was assessed quantitatively by Begg\'s test and Egger\'s test, respectively (*P* \< 0.05 was considered representative of statistically significant publication bias) \[[@B21], [@B22]\]. The statistical analysis was performed using STATA 12.0 software (Stata, College Station, TX, USA).

3. Results {#sec3}
==========

3.1. Study Characteristics {#sec3.1}
--------------------------

Applying the search strategy, 374 papers were found. The titles, abstracts, and full texts of all retrieved articles were reviewed in accordance with the defined criteria. One study by Mendy et al. was excluded because the atherosclerotic disease was diagnosed by self-reported questionnaire, which could be subject to recall bias or misclassification \[[@B23]\]. Overall, 17 studies including a total of 3488 cases and 4241 controls were available for this analysis \[[@B6], [@B13]--[@B17], [@B24]--[@B34]\]. Among these, seven studies with 1810 cases and 1050 controls were available for HSV-2 infection analysis, and all 17 were available for analysis of HSV-1 infection ([Figure 1](#fig1){ref-type="fig"}).

The characteristics of the selected studies were listed in Tables [1](#tab1){ref-type="table"} and [2](#tab2){ref-type="table"}. Of the 17 studies, 14 were published in English and three were written in Chinese. The sample sizes ranged from 15 to 1532. The controls were randomly selected and frequency-matched with the cases on age, region, and gender. Several methods were used to detect HSV-1 and HSV-2 specific antibody, including enzyme-linked immunosorbent assay (ELISA), solid-phase radioimmunoassay (SPRIA), and western blotting (WB). The diseases included myocardial ischemia, stroke, carotid artery disease, and mixed AS lesions (coronary, cerebral, carotid, and peripheral artery involvement) (Tables [1](#tab1){ref-type="table"} and [2](#tab2){ref-type="table"}).

3.2. Effect of HSV-1 Infection on AS Risk {#sec3.2}
-----------------------------------------

The relationships between HSV-1 and HSV-2 infection and the risk of AS were shown in [Table 3](#tab3){ref-type="table"}. Overall, there was statistical evidence of significantly elevated AS risk associated with HSV-1 infection (OR = 1.77; 95% CI = 1.40--2.23) ([Figure 2](#fig2){ref-type="fig"}). In terms of stratified analysis by disease type, there were significant elevated risks in both myocardial ischemia and other types of AS for HSV-1 infection (myocardial ischemia: OR = 1.83; 95% CI = 1.40--2.40; other types of AS: OR = 1.73; 95% CI = 1.02--1.83). When stratified by region, AS risks were elevated in Asians, Europeans, and Americans (Asians: OR = 2.49; 95% CI = 1.57--3.97; Europeans: OR = 1.63; 95% CI = 1.09--2.42; Americans: OR = 1.32; 95% CI = 1.06--1.65). And consistent elevated AS risks for HSV-1 positive subjects were found in all subgroup analysis of age and male proportion (male proportion ≤60%: OR = 2.26; 95% CI = 1.19--4.30; male proportion \>60%: OR = 1.80; 95% CI = 1.40--2.31; age ≤60-year-old: OR = 1.74; 95% CI = 1.26--2.41; age \>60-year-old: OR = 2.52; 95% CI = 1.92--3.30).

3.3. Effect of HSV-2 Infection on AS Risk {#sec3.3}
-----------------------------------------

In total population, HSV-2 positive subjects demonstrated significantly elevated AS risk when compared with the negative ones (OR = 1.37; 95% CI = 1.13--1.67) ([Figure 3](#fig3){ref-type="fig"}). In terms of stratified analysis by disease type, increased risk was only observed in myocardial ischemia and not in other types of AS (myocardial ischemia: OR = 1.66; 95% CI = 1.28--2.15). We also performed stratified analysis by region, age, and male proportion. Significantly elevated risks were observed in male proportion \>60% group and age ≤60-year-old group (male proportion \>60%: OR = 1.61; 95% CI = 1.25--2.07; age ≤60-year-old: OR = 1.41; 95% CI = 1.08--1.85) ([Table 3](#tab3){ref-type="table"}).

3.4. Heterogeneity {#sec3.4}
------------------

There was heterogeneity among studies on HSV-1 infection but not in studies on HSV-2 infection (HSV-1 infection: *P* \< 0.001; *I* ^2^ = 65.60%; HSV-2 infection: *P* = 0.138; *I* ^2^ = 38.2%). To explore sources of heterogeneity across studies, we compared HSV-1 infection according to region of origin, test method, and positivity for HSV-1 infection in controls. We found that the region (*P* \< 0.05), but not test method and the positivity for HSV-1 infection in controls (*P* \> 0.05), might play a role in the initial heterogeneity, which could explain the *I* ^2^ value of 29% in the overall comparison of HSV-1 infection.

3.5. Sensitivity Analysis and Publication Bias {#sec3.5}
----------------------------------------------

There was no significant difference in the pooled OR estimated by omitting one study at a time, indicating that the final results of this meta-analysis were relatively stable and reliable (see Table S1 in Supplementary Material available online at <http://dx.doi.org/10.1155/2016/2630865>). The Begg and Egger tests were conducted to evaluate publication bias. Both revealed no evidence of publication bias in our study; the results were shown in [Table 4](#tab4){ref-type="table"}, Figure S1, and Figure S2.

4. Discussion {#sec4}
=============

Herpesvirus has been implicated in the inflammatory atherosclerotic process \[[@B35]\]. Chronic activation of inflammation by herpesvirus infection is hypothesized to promote atherosclerosis and thrombosis. As the major subtypes of herpesvirus, HSV-1 and HSV-2 have been a concern in relation to AS for many years. However, the existing data are somewhat conflicting. Hence, we deemed it necessary to take a quantitative approach by combining the results of various studies and provide what to our knowledge is the first meta-analysis evaluating the effect of HSV-1 and HSV-2 infection on AS risk.

In the overall analysis, significant increased risk was observed for both HSV-1 and HSV-2 infection, indicating that HSV infection may play an important role in the process of atherogenesis. Some mechanistic studies may explain certain relationships. In 1991, Etingin et al. demonstrated that the endothelial cells infected by HSV might express the adhesion molecule GMP140, which could mediate endothelial cell injury and inflammation \[[@B36]\]. Subsequently, Chirathaworn et al. showed that HSV enhanced the uptake of oxidized low-density lipoprotein in endothelial cells \[[@B37]\]. The atherogenic effect of HSV not only concerned the endothelial cells but also involved VSMCs. It had been reported that more saturated cholesteryl esters and triacylglycerols accumulated in VSMCs infected by HSV than in uninfected cells \[[@B38]\]. In addition, Key et al. concluded that HSV could contribute to deposition of thrombi on atherosclerotic plaques and induce coagulant necrosis by decreasing thrombomodulin activity and increasing tissue factor activity \[[@B39]\]. These in vitro studies demonstrated that HSV exerts effects in almost every step of atherogenesis.

Subgroup analysis suggested that both HSV-1 and HSV-2 infection had a significant risk effect in myocardial ischemia. Borderline significance was found for other types of AS in HSV-1 infection whereas no association was observed between HSV-2 infection and other types of AS. Many studies have reported the detection of HSV-1 DNA in human vascular tissue from different sites. Benditt et al. first found HSV-1 DNA in human vascular tissue from the ascending aorta in patients undergoing coronary bypass surgery \[[@B40]\]. Subsequently, HSV-1 DNA was reported in coronary artery tissue. Chiu et al. detected HSV-1 DNA in plaques from occlusive carotid artery \[[@B41]\], and HSV-1 DNA was also found in atherosclerotic tissues from six types of atherosclerotic lesions by Shi and Tokunaga \[[@B42]\]. However, only one study, by Kotronias and Kapranos, reported the detection of HSV-2 DNA in coronary artery tissue \[[@B43]\]. These data might partially explain the different results from our subgroup analysis. Future studies concerning the association between HSV-2 infection and other types of AS should be performed to confirm our results.

In the stratified analysis of age and male proportion, we found no relationship of HSV-2 infection with risk of AS in male proportion ≤60% group. We presumed that gender difference might account for more than half of the reason. Males are more likely to suffer from AS than females \[[@B44]\]. And androgen appeared to be associated with an increased risk of coronary artery disease by adversely affecting the plasma lipid and lipoprotein profile, producing thrombosis and cardiac hypertrophy \[[@B45]\].

Regarding the subgroup analysis of diverse regions, HSV-1 infection had risk effects on all three subgroups of Asians, Europeans, and Americans. However, the association of HSV-2 infection with AS did not reach statistical significance in any subgroup, possibly because of the limited number of studies and relatively small sample size in each subgroup (two studies of Asians, three studies of Europeans, and two studies of Americans). More well-designed studies with larger sample sizes should be conducted for future validation.

We are aware that this meta-analysis has its own limitations. First, only seven articles with 1810 cases and 1050 controls were available for HSV-2 analysis; the relatively small number of participants made it difficult to perform stratified analysis. Second, our meta-analysis was based on unadjusted estimates; OR adjusted for age and sex should be pooled to provide exact summary estimates if more specific data from studies become available. Third, significant heterogeneity existed in the overall comparison of HSV-1 infection, although we found that regional differences may account for this heterogeneity.

5. Conclusions {#sec5}
==============

Our meta-analysis indicated that HSV-1 and HSV-2 infection potentially increases the risk of AS. However, further large-scale and well-designed studies, including different geographic regions and careful matching between cases and controls, are required to confirm these results.
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======================

###### 

This supplementary material consisted of one table (Table S1) and two figures (Figure S1 and Figure S2). Table S1 showed the ORs and 95% CI of sensitivity analysis concerning HSV-1 and HSV-2. It was no significant difference detected on the pooled OR which was estimated by omitting one study at a time. Figure S1 was Begg\'s funnel plots concerning HSV-1, and Figure S2 concerning HSV-2. The shape of the funnel plots did not reveal any evidence of obvious asymmetry in the overall meta-analysis.
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###### 

Characteristics of literatures included in the meta-analysis concerning HSV-1.

  First author            Year   Country        Region     Disease type             Test method   Male proportion   Age   Sample size   Case size   Control size          
  ----------------------- ------ -------------- ---------- ------------------------ ------------- ----------------- ----- ------------- ----------- -------------- ------ -----
  Jafarzadeh \[[@B24]\]   2011   Iran           Asian      Myocardial ischemia      ELISA         59%               54    180           73          47             20     40
  Heltai \[[@B25]\]       2004   Hungary        European   Myocardial ischemia      ELISA         ---               ---   129           59          24             32     14
  Vahdat \[[@B26]\]       2007   Iran           Asian      Myocardial ischemia      ELISA         49%               ---   1754          198         24             1327   205
  Mundkur \[[@B17]\]      2012   UK             European   Myocardial ischemia      ELISA         68%               53    866           240         193            214    219
  Prasad \[[@B27]\]       2002   America        American   Myocardial ischemia      ELISA         61%               56    375           211         35             102    27
  Georges \[[@B28]\]      2003   Germany        European   Myocardial ischemia      ELISA         73%               62    1324          922         69             280    53
  Lindberg \[[@B29]\]     1997   Sweden         European   Carotid artery disease   SPRIA         ---               ---   534           198         69             190    77
  Siscovick \[[@B13]\]    2000   America        American   Myocardial ischemia      WB            63%               74    618           191         22             333    72
  Guan \[[@B15]\]         2012   China          Asian      Myocardial ischemia      ELISA         62%               56    252           71          31             60     90
  Zhu \[[@B30]\]          2000   America        American   Myocardial ischemia      ELISA         63%               57    233           133         25             59     16
  Kis \[[@B14]\]          2007   Hungary        European   Stroke                   ELISA         58%               52    111           24          35             8      44
  Adam \[[@B31]\]         1987   America        American   Mixed AS lesions         SPRIA         100%              58    226           75          38             69     44
  Sorlie \[[@B16]\]       2000   America        American   Myocardial ischemia      SPRIA         52%               55    726           166         55             379    126
  Al-Ghamdi \[[@B6]\]     2012   Saudi Arabia   Asian      Mixed AS lesions         ELISA         64%               56    90            72          3              14     1
  Pan \[[@B32]\]          2005   China          Asian      Myocardial ischemia      ELISA         48%               62    127           46          16             22     43
  Pan \[[@B33]\]          1999   China          Asian      Myocardial ischemia      ELISA         70%               ---   60            24          6              22     8
  Liu \[[@B34]\]          2004   China          Asian      Myocardial ischemia      ELISA         73%               67    124           72          21             19     12

HSV-1: herpes simplex virus type 1; ELISA: enzyme-linked immunosorbent assay; SPRIA: solid-phase radioimmunoassay; WB: western blot; AS: atherosclerosis.

###### 

Characteristics of literatures included in the meta-analysis concerning HSV-2.

  First author            Year   Country   Region     Disease type             Test method   Male proportion   Age   Sample size   Case size   Control size        
  ----------------------- ------ --------- ---------- ------------------------ ------------- ----------------- ----- ------------- ----------- -------------- ---- -----
  Jafarzadeh \[[@B24]\]   2011   Iran      Asian      Myocardial ischemia      ELISA         59%               54    180           34          86             17   43
  Georges \[[@B28]\]      2003   Germany   European   Myocardial ischemia      ELISA         73%               62    1324          139         852            27   306
  Lindberg \[[@B29]\]     1997   Sweden    European   Carotid artery disease   SPRIA         ---               ---   534           64          203            66   201
  Guan \[[@B15]\]         2012   China     Asian      Myocardial ischemia      ELISA         62%               56    252           56          46             57   93
  Zhu \[[@B30]\]          2000   America   American   Myocardial ischemia      ELISA         63%               57    233           84          74             32   43
  Kis \[[@B14]\]          2007   Hungary   European   Stroke                   ELISA         58%               52    111           23          36             14   38
  Adam \[[@B31]\]         1987   America   American   Mixed AS lesions         SPRIA         100%              58    226           30          83             31   82

HSV-2: herpes simplex virus type 2; ELISA: enzyme-linked immunosorbent assay; SPRIA: solid-phase radioimmunoassay; AS: atherosclerosis.

###### 

Pooled OR and 95% CI of stratified meta-analysis.

  Variables              HSV-1   HSV-2                                                                                                      
  ---------------------- ------- ----------------------- ------------- ------ --------- --- ----------------------- ------------- --------- -------
  Total                  17      **1.77 (1.40--2.23)**   **\<0.001**   65.6   \<0.001   7   **1.37 (1.13--1.67)**   **0.002**     38.2      0.138
  Disease type                                                                                                                               
   Myocardial ischemia   13      **1.83 (1.40--2.40)**   **\<0.001**   69.6   \<0.001   4   **1.66 (1.28--2.15)**   **\<0.001**   \<0.001   0.409
   Other types of AS     4       **1.37 (1.02--1.83)**   **0.035**     45.8   0.137     3   1.05 (0.77--1.41)       0.777         \<0.001   0.410
  Region                                                                                                                                     
   Asian                 7       **2.49 (1.57--3.97)**   **\<0.001**   61.3   0.017     2   1.47 (0.75--2.86)       0.261         59.4      0.116
   European              5       **1.63 (1.09--2.42)**   **0.017**     73.2   0.005     3   1.40 (0.87--2.26)       0.168         61.9      0.072
   American              5       **1.32 (1.06--1.65)**   **0.014**     11.9   0.338     2   1.22 (0.82--1.83)       0.323         22.2      0.257
  Male proportion                                                                                                                            
   ≤60%                  5       **2.26 (1.19--4.30)**   **0.013**     84.0   \<0.001   2   1.26 (0.75--2.13)       0.381         3.6       0.308
   \>60%                 10      **1.80 (1.40--2.31)**   **\<0.001**   47.9   0.044     4   **1.61 (1.25--2.07)**   **\<0.001**   26.8      0.251
  Age                                                                                                                                        
   ≤60-year-old          9       **1.74 (1.26--2.41)**   **0.001**     67.4   0.002     5   **1.41 (1.08--1.85)**   **0.012**     14.9      0.320
   \>60-year-old         4       **2.52 (1.92--3.30)**   **\<0.001**   46.5   0.132     1   1.85 (1.20--2.85)       0.005         ---       ---

HSV-1: herpes simplex virus type 1; HSV-2: herpes simplex virus type 2; AS: atherosclerosis; OR: odds ratio; *P* ~Het~: the *P* value of heterogeneity; ---: no data. The results were in bold, if the 95% CI excluded 1 or *P* \< 0.05.

###### 

The results of Begg\'s and Egger\'s test for publication bias.

  HSV type   Begg\'s test   Egger\'s test          
  ---------- -------------- --------------- ------ -------
  HSV-1      1.69           0.091           1.71   0.107
  HSV-2      0.00           1.000           0.15   0.887

HSV: herpes simplex virus; HSV-1: herpes simplex virus type 1; HSV-2: herpes simplex virus type 2.
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